Pharmacological inhibition of NOX reduces atherosclerotic lesions, vascular ROS and immune-inflammatory responses in diabetic Apoe -/- mice

Diabetologia

Volumn 57, Issue 3, 2014, Pages 633-642

  Di Marco, E ^a,b   Gray, S P ^a   Chew, P ^a   Koulis, C ^a   Ziegler, A ^b   Szyndralewiez, C ^c   Touyz, R M ^d,e   Schmidt, H H H W ^f   Cooper, M E ^a   Slattery, R ^b   Jandeleit Dahm, K A ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c GENKYOTEX SA   (Switzerland)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Atherosclerosis; Diabetes; Immune system; Inflammation; NOX

Indexed keywords

APOLIPOPROTEIN E; GKT137831; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL; ATHEROSCLEROSIS; BIOSYNTHESIS; DEFICIENCY; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; DRUG EFFECTS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; INFLAMMATION; MALE; METABOLISM; MOUSE; OXIDATION REDUCTION REACTION; PATHOLOGY; PLAQUE, ATHEROSCLEROTIC; THORACIC AORTA;

ANIMALS; AORTA, THORACIC; APOLIPOPROTEINS E; ATHEROSCLEROSIS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MICE; NADPH OXIDASE; OXIDATION-REDUCTION; PLAQUE, ATHEROSCLEROTIC; PYRAZOLES; PYRIDINES; REACTIVE OXYGEN SPECIES;

EID: 84894524407     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-3118-3     Document Type: Article

References (50)

1. Kannel WB, McGee DL (1979) Diabetes and cardiovascular disease. The Framingham study. J Am Med Assoc 241:2035-2038
2. Mäkinen VP, Forsblom C, Thorn LM et al (2009) Network of vascular diseases, death and biochemical characteristics in a set of 4,197 patients with type 1 diabetes (The FinnDiane Study). Cardiovasc Diabetol 8:54
3. Ross R (1999) Atherosclerosis - an inflammatory disease. N Engl J Med 340:115-126
4. Lassègue B, Griendling KK (2010) NADPH oxidases: functions and pathologies in the vasculature. Arterioscler Thromb Vasc Biol 30:653-661
5. Hansson GK, Hermansson A (2011) The immune system in atherosclerosis. Nat Immunol 12:204-212
6. Piga R, Naito Y, Kokura S, Handa O, Yoshikawa T (2007) Short-term high glucose exposure induces monocyte-endothelial cells adhesion and transmigration by increasing VCAM-1 and MCP-1 expression in human aortic endothelial cells. Atherosclerosis 193:328-334
7. Kanter JE, Bornfeldt KE (2013) Inflammation and diabetes-accelerated atherosclerosis: myeloid cell mediators. Trends Endocrinol Metab 24:137-144
8. Soro-Paavonen A, Watson AMD, Li J et al (2008) Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 57:2461-2469
9. Hansson GK, Holm J, Jonasson L (1989) Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 135:169-175
10. Frostegård J, Ulfgren AK, Nyberg P et al (1999) Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145:33-43
11. Van Der Wal AC, Becker AE, van Der Loos CM, Das PK (1994) Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 89:36-44
12. Baynes JW (1991) Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412
13. Griendling KK, Ushio-Fukai M (1997) NADH/NADPH oxidase and vascular function. Trends Cardiovasc Med 7:301-307
14. Hink U, Li H, Mollnau H et al (2001) Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88:E14-E22
15. Sedeek M, Callera G, Montezano A et al (2010) Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. Am J Physiol Ren Physiol 299:F1348-F1358
16. Guzik TJ, Sadowski J, Guzik B et al (2006) Coronary artery superoxide production and nox isoform expression in human coronary artery disease. Arterioscler Thromb Vasc Biol 26:333-339
17. Ding H, Hashem M, Triggle C (2007) Increased oxidative stress in the streptozotocin-induced diabetic apoE-deficient mouse: changes in expression of NADPH oxidase subunits and eNOS. Eur J Pharmacol 561:121-128
18. Guzik TJ, Mussa S, Gastaldi D et al (2002) Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105:1656-1662
19. Wendt MC, Daiber A, Kleschyov AL et al (2005) Differential effects of diabetes on the expression of the gp91 phox homologues nox1 and nox4. Free Radic Biol Med 39:381-391
20. Gray SP, Di Marco E, Okabe J et al (2013) NADPH Oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation 127:1888-1902
21. Marumo T, Schini-Kerth VB, Fisslthaler B, Busse R (1997) Platelet-derived growth factor-stimulated superoxide anion production modulates activation of transcription factor NF-κB and expression of monocyte chemoattractant protein 1 in human aortic smooth muscle cells. Circulation 96:2361-2367
22. Kunsch C, Medford RM (1999) Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 85:753-766
23. Cybulsky MI, Iiyama K, Li H et al (2001) A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Investig 107:1255-1262
24. Mach F, Sauty A, Iarossi AS et al (1999) Differential expression of three t lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Investig 104:1041-1050
25. Nareika A, Sundararaj KP, Im YB, Game BA, Lopes-Virella MF, Huang Y (2009) High glucose and interferon gamma synergistically stimulate MMP-1 expression in U937 macrophages by increasing transcription factor STAT1 activity. Atherosclerosis 202:363-371
26. Esposito K, Nappo F, Marfella R et al (2002) Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106:2067-2072
27. Hsueh W, Abel ED, Breslow JL et al (2007) Recipes for creating animal models of diabetic cardiovascular disease. Circ Res 100:1415-1427
28. Candido R, Jandeleit-Dahm KA, Cao Z et al (2002) Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 106:246-253
29. Krege JH, Hodgin JB, Hagaman JR, Smithies O (1995) A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 25:1111-1115
30. Aoyama T, Paik YH, Watanabe S et al (2012) Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology 56:2316-2327
31. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA (1987) Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 68:231-240
32. Feng B, Zhang D, Kuriakose G, Devlin CM, Kockx M, Tabas I (2003) Niemann-Pick C heterozygosity confers resistance to lesional necrosis and macrophage apoptosis in murine atherosclerosis. Proc Natl Acad Sci U S A 100:10423-10428
33. Elmarakby AA, Loomis ED, Pollock JS, Pollock DM (2005) NADPH oxidase inhibition attenuates oxidative stress but not hypertension produced by chronic ET-1. Hypertension 45:283-287
34. Sheehan AL, Carrell S, Johnson B, Stanic B, Banfi B, Miller FJ (2011) Role for Nox1 NADPH oxidase in atherosclerosis. Atherosclerosis 216:321-326
35. Kanter JE, Averill MM, Leboeuf RC, Bornfeldt KE (2008) Diabetes-accelerated atherosclerosis and inflammation. Circ Res 103:e116-e117
36. Stentz FB, Kitabchi AE (2005) Hyperglycemia-induced activation of human T-lymphocytes with de novo emergence of insulin receptors and generation of reactive oxygen species. Biochem Biophys Res Commun 335:491-495
37. Lindley S, Dayan CM, Bishop A, Roep BO, Peatman M, Tree TIM (2005) Defective suppressor function in CD4+CD25+ T cells from patients with type 1 diabetes. Diabetes 54:92-99
38. - mice. BMC Immunol 11:58
39. Gupta S, Pablo AM, Jiang XC, Wang N, Tall AR, Schindler C (1997) IFN-γ, potentiates atherosclerosis in ApoE knock-out mice. J Clin Investig 99:2752-2761
40. Zhou X, Nicoletti A, Elhage R, Hansson GK (2000) Transfer of CD4+ T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 102:2919-2922
41. Uyemura K, Demer LL, Castle SC et al (1996) Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Investig 97:2130-2138
42. McLaren JE, Ramji DP (2009) Interferon gamma: a master regulator of atherosclerosis. Cytokine Growth Factor Rev 20:125-135
43. Kyaw T, Winship A, Tay C et al (2013) Cytotoxic and proinflammatory CD8+ T lymphocytes promote development of vulnerable atherosclerotic plaques in apoE-deficient mice. Circulation 127:1028-1039
44. Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105:1135-1143
45. Falk E, Shah PK, Fuster V (1995) Coronary plaque disruption. Circulation 92:657-671
46. Thim T, Hagensen MK, Bentzon JF, Falk E (2008) From vulnerable plaque to atherothrombosis. J Intern Med 263:506-516
47. Burke AP, Kolodgie FD, Zieske A et al (2004) Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol 24:1266-1271
48. Brito C, Naviliat M, Tiscornia AC et al (1999) Peroxynitrite inhibits T lymphocyte activation and proliferation by promoting impairment of tyrosine phosphorylation and peroxynitrite-driven apoptotic death. J Immunol 162:3356-3366
49. Bobryshev YV (2010) Dendritic cells and their role in atherogenesis. Lab Investig 90:970-984
50. Sheng KC, Pietersz GA, Tang CK, Ramsland PA, Apostolopoulos V (2010) Reactive oxygen species level defines two functionally distinctive stages of inflammatory dendritic cell development from mouse bone marrow. J Immunol 184:2863-2872